Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018

  • ID: 4592408
  • Report
  • 319 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Formation Biologics Inc
  • iBio Inc
  • Nuevolution AB
  • Samumed LLC
  • MORE
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights:

This latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 15, 9, 1, 31 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Formation Biologics Inc
  • iBio Inc
  • Nuevolution AB
  • Samumed LLC
  • MORE
Introduction

Systemic Sclerosis (Scleroderma) - Overview

Systemic Sclerosis (Scleroderma) - Therapeutics Development

Systemic Sclerosis (Scleroderma) - Therapeutics Assessment

Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development

Systemic Sclerosis (Scleroderma) - Drug Profiles

Systemic Sclerosis (Scleroderma) - Dormant Projects

Systemic Sclerosis (Scleroderma) - Discontinued Products

Systemic Sclerosis (Scleroderma) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Abide Therapeutics Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Anima Biotech Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by BriaCell Therapeutics Corp, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Co, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Capella Bioscience Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Formation Biologics Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Fresenius SE & Co KGaA, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by GNI Group Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corp LLC, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Link Genomics Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by MallInckrodt Plc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Nuevolution AB, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Pfizer Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Resolys Bio Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Seattle Genetics Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Unity Biotechnology Inc, H2 2018

Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, H2 2018

Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2018

Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abide Therapeutics Inc
  • AnaMar AB
  • Anima Biotech Ltd
  • arGentis Pharmaceuticals LLC
  • Bayer AG
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • BriaCell Therapeutics Corp
  • Bristol-Myers Squibb Co
  • Capella Bioscience Ltd
  • Chugai Pharmaceutical Co Ltd
  • Covis Pharmaceuticals Inc
  • CSL Ltd
  • Cumberland Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Fibrocell Science Inc
  • Formation Biologics Inc
  • Fresenius SE & Co KGaA
  • GenKyoTex SA
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GNI Group Ltd
  • iBio Inc
  • Inventiva
  • Kadmon Corp LLC
  • Leadiant Biosciences Inc
  • Link Genomics Inc
  • MallInckrodt Plc
  • Nuevolution AB
  • Patagonia Pharmaceuticals LLC
  • PDX Pharmaceuticals LLC
  • Peptinov SAS
  • Pfizer Inc
  • ProMetic Life Sciences Inc
  • Resolys Bio Inc
  • Ribomic Inc
  • Samumed LLC
  • Sanofi
  • Seattle Genetics Inc
  • Stemline Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Unity Biotechnology Inc
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll